{"id":504,"date":"2024-02-02T14:35:20","date_gmt":"2024-02-02T14:35:20","guid":{"rendered":"https:\/\/pureoptical.com\/?p=504"},"modified":"2024-04-23T15:25:09","modified_gmt":"2024-04-23T15:25:09","slug":"can-areds2-prevent-macular-degeneration","status":"publish","type":"post","link":"https:\/\/pureoptical.com\/blog\/can-areds2-prevent-macular-degeneration\/","title":{"rendered":"Can AREDS2 Prevent Macular Degeneration?"},"content":{"rendered":"

Macular degeneration, specifically age-related macular degeneration (AMD), is a significant cause of vision loss among older adults, impacting millions worldwide. As the population ages, the search for effective prevention strategies becomes increasingly critical. One prominent focus has been on dietary supplements, particularly the formulation known as AREDS2. This article explores the potential of AREDS2 in preventing macular degeneration<\/a>, shedding light on its ingredients, efficacy, and how it may fit into broader AMD management strategies.<\/span><\/p>\n

Understanding macular degeneration<\/span><\/h2>\n

Macular degeneration<\/span><\/a>, more formally known as age-related macular degeneration (AMD), is a common eye condition that primarily affects people over the age of 50. It occurs when the macula, the part of the retina responsible for clear vision in the direct line of sight, deteriorates over time. The condition is divided into two main types: dry (atrophic) and wet (neovascular).\u00a0<\/span><\/p>\n

Dry AMD, which accounts for approximately <\/span>80-90% of cases<\/span><\/a>, is characterized by the thinning of the macula and the presence of drusen, small yellow deposits that form beneath the retina. Wet AMD, though less common, is more severe and involves the growth of abnormal blood vessels under the retina and macula, leading to bleeding, leaking, and scarring, which can result in rapid and severe vision loss<\/a>.<\/span><\/p>\n

\ud83d\udc40 Read more: <\/span>Dry or Wet Macular Degeneration – Which Is Worse?<\/span><\/a><\/p>\n

The inception of AREDS and AREDS2<\/span><\/h2>\n

The development and study of the Age-Related Eye Disease Study (AREDS) and its successor, AREDS2, represent significant milestones in the research on <\/span>nutritional supplements<\/span><\/a> and their impact on AMD and cataracts. Initiated by the National Eye Institute (NEI), the original AREDS study was a major clinical trial designed to investigate the effects of a specific combination of vitamins and minerals on the progression of AMD and cataracts.<\/span><\/p>\n

The study, which concluded in 2001, found that the original AREDS formula\u2014comprising vitamin C, vitamin E, beta-carotene, zinc, and copper\u2014significantly reduced the risk of advanced AMD progression by about 25% over a five-year period for individuals with intermediate AMD or those with advanced AMD in one eye.<\/span><\/p>\n

Buoyed by the success of AREDS, researchers embarked on a second study, AREDS2, to refine the formula and assess the effects of adding other nutrients thought to be beneficial for eye health. AREDS2 aimed to evaluate the addition of lutein and zeaxanthin (which are carotenoids found in the eye) in place of beta-carotene, which was associated with an increased risk of lung cancer in smokers. The study also tested the addition of omega-3 fatty acids (DHA and EPA) and the effects of lowering zinc doses.<\/span><\/p>\n

Concluding in 2013, AREDS2 found that replacing beta-carotene with lutein and zeaxanthin was safer and could reduce the risk of lung cancer. Furthermore, the AREDS2 formula was associated with a further reduction in the risk of AMD progression beyond the original AREDS formula, particularly in participants with low dietary intake of lutein and zeaxanthin.<\/span><\/p>\n

\"\"<\/p>\n

The AREDS2 formula<\/span><\/h2>\n

The AREDS2 formula consists of the following:<\/span><\/p>\n